miR-155 expression in antitumor immunity: The higher the better?

Area of Science:

• Molecular Biology
• Immunology
• Oncology

Background:

• MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression.
• Aberrant miRNA expression is linked to numerous pathologies, including cancers.
• MiR-155 is a key regulator of innate and adaptive immune responses, with altered expression in various malignancies.

Purpose of the Study:

• To review the dual oncogenic and antitumor roles of miR-155, focusing on its dose-dependent effects.
• To examine miR-155's impact on immune cell antitumor activity in leukemias and solid tumors.
• To explore miR-155's potential therapeutic application in cancer immunotherapy.

Main Methods:

• Review of existing literature on miR-155 function in cancer and immunity.
• Analysis of dose-dependent effects of miR-155 in different cancer types.
• Investigation of miR-155's interaction with immune checkpoints.

Main Results:

• MiR-155 exhibits context-dependent roles; intermediate levels can be detrimental, while high levels are often beneficial in cancer.
• High miR-155 expression demonstrates antitumor potential in both leukemias and solid tumors.
• MiR-155 targets transcripts encoding immune checkpoints like CTLA-4 and PD-L1.

Conclusions:

• MiR-155's dose-dependent activity highlights its complex role in cancer.
• Elevating miR-155 levels in immune cells may enhance the efficacy of current cancer immunotherapies.
• Further research into miR-155 modulation could lead to novel therapeutic strategies.